Periodic Reporting for period 3 - HEDIMED (Human Exposomic Determinants of Immune Mediated Diseases)
Periodo di rendicontazione: 2023-01-01 al 2023-12-31
HEDIMED focuses on common chronic IMDs that cause a significant disease burden, including type 1 diabetes, celiac disease, allergies and asthma. Exposomic disease determinants and the underlying biological pathways are identified using advanced technologies and datamining tools. Particular emphasis is paid on early fetal and childhood exposome since the disease process is known to start early. Inclusion of several IMDs makes it possible to identify determinants that are common for many IMDs facilitating the development of widely applicable treatments. HEDIMED generates a toolbox that offers various kind of data, new technologies, latest information, and functional tools for several stakeholders to facilitate the efforts to find ways to control the IMD epidemic. HEDIMED works also together with the other projects funded within the Human Exposome program call H2020 SC1-BHC-2018-2020 forming the European Human Exposome Network (EHEN), the largest scientific network in the world focusing on the human exposome (https:// www.humanexposome.eu/). HEDIMED is currently in an active research phase. You can follow its progress via the HEDIMED web page, X (former Twitter) @HEDIMED2020 and newsletters.
• identification of research priorities of HEDIMED based on the HEDIMED resources and the existing knowledge gaps in the fields of type 1 diabetes, celiac disease, allergies, and asthma.
• detailed inventory of methodologies available in the different HEDIMED institutions
• detailed characterization of clinical cohorts and clinical trials, and mapping of data and sample resources available for various kinds of analyses.
• development of new analytical methods for the evaluation of exposomic impacts.
• continuing the recruitment of study subjects to clinical cohorts and trials, and collection of dedicated specimens for HEDIMED research.
• ongoing laboratory analyses of biological samples collected in clinical cohorts and trials.
• characterization of living environment using satellite data and analysis of environmental samples.
• analyses of the mechanisms of exposomic impacts in human organoids and cell models.
• ongoing development of the HEDIMED toolbox including the Internal Data Analysis Platform for robust data analyses from multiple cohorts and Public Platform for efficient dissemination.
• construction of system dynamic modelling tools for the prediction of the impacts of exposome-based interventions in the prevention of type 1 diabetes and celiac disease.
• publication of the results from these studies in scientific journals and research meetings.
• dissemination the research findings and participation in the public discussion on the role of exposome in human health via X (former Twitter) channel @HEDIMED2020.
• posting of blogs on project web pages on actual topics which are important for the understanding the mission of HEDIMED.
• publication of newsletters which are accessible via web pages and by email disseminations.
• construction and continuous updating of HEDIMED web page (https://www.hedimed.eu/).
In summary, HEDIMED has created a solid infrastructure for successful research, impact generation and communication for the coming years. The project is currently in active analytical phase generating new information about exposomic determinants of IMDs.